The model organism Agrobacterium tumefaciens is a soil bacterium and the causative agent of the crown gall disease in dicotyledonous plant species(1)
. The VirA receptor of A. tumefaciens recognizes phenols and initiates a signal transduction cascade for the expression of virulence (vir) genes. The initiation of an infection is controlled by a two-component system comprised of the transmembrane-bound sensor (VirA ) and the intracellular response regulator (VirG; (1)
). Upon activation by phenol 3,5-dimethoxyacetophenone (acetosyringone), the histidine kinase VirA is autophosphorylated at its His-474 residue (3)
; the phosphor is then transferred to VirG(4)
(Figure 1). VirG acts as a transcription factor and binds to a promoter containing the virulence box (vir Box); for example, the virB promoter(4)
Expression System and BioBricks
The aim of our project was to transfer the very specific recognition and signaling mechanisms of A. tumefaciens into a standard expression system. We subcloned virA and virG into the E. coli TOP10 cells. To exclude a coactivation of other A. tumefaciens pathways, we also subcloned the inducible promoter virB. All the plasmid constructs we generated were conform using the guidelines of the BioBrick standard, and thus, can be assembled easily in any chosen order.
Read out system
We built a BioBrick with a luminescent read out system to quantify the target substance. For this purpose the virG inducible and vir box-containing promotor virB were cloned upstream of the firefly luciferase gene.
To design a new biosensor based on the receptor binding site of VirA a proof of principle had to be established. We used the native ligand of VirA, the phenol acetosyringone, to induce a luciferase-based light signal in E.coli (Figure 2).
BioBrick Assembly —Suffix Insertion
The insert was digested with XbaI and PstI and the pGL4.10[luc2] vector was digested with SpeI and PstI according to standard protocols. Following digestion, the vector was phosphorylated using shrimp alcaline phosphatase, cleaned with a PCR clean-up kit and then ligated with the BioBrick insert (Figure 3).
Cultivation for measuring mRFP and Luciferase expression
E. coli Top 10 glycerol stocks were transformed with the pGL4.10[luc2]-BioBrick construct and cultivated with appropriate antibiotics at 37°C with shaking at 175 rpm. The handling of the bacterial culture depends on the read out-strategy that will be used.
Measuring of Luciferase
For luciferase detection we used the Promega Luciferase Assay System according to the manufacturer’s protocol. Bacterial cells were lysed in a high salt buffer (1M K2HPO4, 20mM EDTA, pH 7.8). Ninety microliters of the sample was exposed to one freeze-thaw cycle at –80°C. Following the freeze-thaw cycle, 300µl of freshly prepared lysis mix (1X Cell Culture Lysis Reagent, 1.25mg/ ml lysozyme, 2.5mg/ml BSA) was added and mixed. The luminescent signal was detected using the Promega GloMax®-Multi Detection System with dual injector. (Injection volume of Luciferase Assay Reagent: 100µl, delay: 20 seconds, Integration: 3 seconds).
We established the complete VirA/G signaling system from A. tumefaciens in E. coli. A basal expression of luciferase without any acetosyringone induction could be obtained. After adding 50µM and 150µM of acetosyringone, we measured and characterized an induction signal using the reporter genes mRFP and luciferase. Induction with acetosyringone resulted in an increase in luciferase expression levels (compared to the basal expression; Figure 4).
To characterize the luciferase expression response to acetosyringone induction, we calculated a fitting curve. Following the approach described in Nelson et al. (8)
, we used a dose response function and a logistic equation(1)
for the data calculation of the receptor system. The luminescent response was proportional to the concentration of acetosyringone used for induction(3)
Next we created three new BioBricks containing the virA, virG or vir promoter. We also tried to create a light signal that is visible to the naked eye. For this purpose we added genetic amplifiers (Cambridge, iGEM 2007, amplifier project) to our luciferase BioBrick. This amplified luciferase read out was coupled with the VirA/G signaling system to visualize the induction behavior. Although the amplifiers gave visible luciferase readout, the basal expression of the vir promoter was also amplified. Due to the strong amplification of both the basal expression and the induced expression, the VirA/G system could not be clearly distinguished from uninduced samples (Figure 6).
In this project we established an E.coli-based biosensor that is capable of sensing and measuring acetosyringone induction. Besides the functionality of the VirA/VirG two component system in E.coli, which was shown previously by Jung et al. (9)
, we combined the signaling pathway with a luciferase-based read out system. We further demonstrated that the luciferase intensity correlated with the concentration of acetosysringone used to induce the cells. When this data was fitted to a dose-response curve, it was shown to be in close relation to the expected biological function of the receptor. The basal luciferase expression that was present in the uninduced system is the result of a leaking virB promoter. However, when the cells were induced with a saturating concentration of acetosyringone, the luciferase expression was up to twofold higher than for the uninduced state.
Furthermore we provided eight new BioBrick parts to the database, which can be used in prospective projects.
To design a novel biosensor using a directed evolution driven approach to receptor modification, we established an error prone PCR protocol as well as a screening system (data not shown). In the ongoing work we are going to use an iterative process to optimize the receptor specificity and selectivity to closely related phenolic compounds ( e.g., capsaicine).
The iGEM Project was supported by the Center for Biotechnology, CeBiTec at the University Bielefeld, Germany. Additional Project Funding was provided by: BIO.NRW Cluster Biotechnology of federal state of North Rhine-Westfalia, Evonik GmbH, Promega GmbH, PlasmidFactory & Co.KG and A.S.I.